Mission Statement The mission of the Wyoming State Board of Pharmacy is to promote and protect the health and safety of the public by regulating the practice of pharmacy.
COVID Vaccine Update
On May 10th, FDA expanded the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents 12 years of age and older.
Spring Renewals Now Open
The 2021 renewal season for the following license types is now open: Resident Retail and Institutional Pharmacies, Resident Telepharmacies, Non-Resident Pharmacies, Wholesale Distributors, Third-Party Logistics Providers, and Individual Controlled Substance Registrations.
Online renewal is ONLY available for Non-Resident Pharmacies, Wholesale Distributors and Individual Controlled Substance Registrations. Renewal Notices and Online Renewal Instructions were mailed on April 1, 2021.
Please email the Board office if you have any questions about your renewal.
Extension of Public Comment Period
Due to unforeseen circumstances, the public comment period for the proposed revisions to the Wyoming Pharmacy Act Rules Chapter 16: Immunization Regulations has been extended. Requests for copies of the proposed revisions may be addressed to the Board executive director at 1712 Carey Avenue, Suite 200, Cheyenne, WY 82002. The proposed amended rules and new chapter are posted on the Wyoming Secretary of State website. Comments may be submitted to the Board address above by mail or to firstname.lastname@example.org on or before May 8th, 2021, at 5 pm MDT.
Issuing and Dispensing Prescriptions for Controlled Substances in 2021
As a reminder, pursuant to Wyoming Statute 35-7-1030, controlled substances are now required to be electronically prescribed. The requirements for electronic prescribing systems and exemptions to the electronic prescribing requirement can be found in the Wyoming Controlled Substances Act Rules Chapter 10.
Distribution of controlled substances
It is the Board’s understanding that many resident pharmacies have been distributing controlled substances to practitioners for office dispensing. While the Board does not prohibit this practice, there are many requirements that should be followed in order for pharmacies to be compliant with federal law.
The Board strongly encourages all licensees that may be engaged in this activity to review their current processes to ensure compliance with state and federal law. The following federal provisions are being provided to aid in that review. As a reminder, the Board’s rules and DEA regulations prohibit prescriptions from being issued in order for practitioners to obtain controlled substances for supplying the practitioner for the purpose of general dispensing to patients.
21CFR1304.22 - Records for manufacturers, distributors, dispensers, researchers, importers, exporters, registrants that reverse distribute, and collectors
21CFR1305.03 - Distributions requiring a Form 222 or a digitally signed electronic order
21CFR1305.06 - Persons entitled to fill orders for C-I and C-II substances
21CFR1307.11 - Distribution by dispenser to another practitioner
The Board would like to remind all pharmacies that if they are engaged in this practice, it would be considered distribution. Licensees should not be reporting the distribution of controlled substances as prescriptions into the Wyoming Online Prescription Database (WORx). Please direct any questions to the Board office in writing to email@example.com.
Butalbital Schedule Status in Wyoming
It has come to the Board's attention that there are questions surrounding butalbital scheduling. The Wyoming Controlled Substances Act (Wyoming Statute 35-7-1018(c)(iii)) lists “any substance which contains any quantity of a derivative of barbituric acid or any salt thereof" as a schedule III-controlled substance. While there are butalbital products listed on the DEA’s list of Exempted Prescription Products, including Fioricet (butalbital/acetaminophen/caffeine), Wyoming does not have a similar list of exempted products. All butalbital-containing products, therefore, are schedule III-controlled substances in Wyoming and must be treated as such.
The Board of Pharmacy has received multiple inquiries regarding COVID-19 and the impact on the practice of pharmacy in Wyoming. The Board continues to engage with State partners to monitor the situation. Based on current recommendations, some of the Board staff will be working remotely. If you need to visit with a member of the staff in person, we strongly encourage making an appointment by calling the Board office at 307-634-9636 or emailing firstname.lastname@example.org.
The Board will continue to update this document with new information.
1712 Carey Ave. Ste 200 Cheyenne, WY 82002
Phone: 307-634-9636 Fax: 307-634-6335